Response to Breton Et Al. Specificity of TP53 Mutation Screening Methods in Cancerous Tissues
Osamu Yamanoshita,Takeo Kubota,Jun Hou,Yu‐Min Ping,Xiulan Zhang,Xiangping Li,Shao‐Sen Li,Xiao‐Xian Li,De‐Chen Zhu,Yoshimitsu Fukushima,Tamic Nakajima
DOI: https://doi.org/10.1002/ijc.21224
2005-01-01
International Journal of Cancer
Abstract:I have read with great interest the letter of Breton et al. The letter points out the low specificity of denaturing high-performance liquid chromatography (DHPLC) to screened p53 mutations in my study, together with their proposal of several methods to resolve several points. Allow me to respond to the 2 important points. First, Breton et al. noted that false-positives in p53 mutations could be reduced by using a laser capture microdissection as reported by Ito et al.1 and Dillon et al.2 One point sampling from the section by this instrument, however, did not always succeed in picking up the tissue with p53 mutations. Second, the DHPLC method reported by Leonard et al.,3 which Breton et al. recommended, is complex. In addition, Leonard et al. mixed wild-type PCR product with sample PCR products before applying DHPLC.3 In this case, if the ratio of the mutated DNA is low in a sample, it is easy to overlook the mutations. Therefore, the higher the rates of cells without p53 mutations are in the esophageal cancer tissue, the lower the rates of detection of p53 mutations, not only because of the DHPLC but also the direct sequencing method. Deininger et al. reported that the detection limit of DHPLC is twice as high as that of the direct sequencing.4 Even in this case, mutations could not be detected by DHPLC if the rates of PCR product with mutations were 15% or less.4 The detection ability of direct sequence analysis may be preferable to that of DHPLC if the detection ability of the DNA sequencer is raised. To quote Breton et al.: “It has indeed often been demonstrated that direct sequencing has a low sensitivity compared to screening methods such as DGGE5 or DHPLC.6” In comparison of DHPLC and direct sequencing, Jones et al.,6 used the ABI-377 sequencer (Applied Biosystems,), which is lower in sensitivity than the currently used instrument (ABI-3100; Applied Biosystems). The difference in the sensitivity of gene mutation detection between DHPLC and direct sequencing would be less if a more sensitive sequencer (for example, ABI-3100) were used. I think that further technical improvement is necessary to analyze mutations and polymorphisms in the tissue and blood cells including lower rates of cells with p53 mutation. Yours sincerely, Osamu Yamanoshita